Delcath is dedicated to...

Concentrating the Power of Chemotherapy

We’re focused on chemosaturation of the liver. The hope—to manage life-threatening liver metastases through isolation of the organ, saturation with ultra-high doses of a chemotherapeutic agent, and filtration of the blood to minimize systemic toxicity before returning it to the patient’s system.

Because chemosaturation is intended to be a minimally invasive, repeatable way to deliver high-dose chemotherapy to the liver, we believe it has the potential to complement existing systemic treatments for a patient’s primary disease.

Our proprietary Hepatic CHEMOSAT^® Delivery System has obtained CE Mark approval in Europe for administration of melphalan hydrochloride to the liver. In the United States, Delcath’s system for chemosaturation is an investigational product and is not approved by the U.S. Food and Drug Administration.

EXPLORE THE SITE